ARCH-backed biotech emerges with $85M and a bold claim: A new human hormone can reverse a key effect of aging

Dugar, Schreiner and Cox are now forming a company called Epirium around that finding and the subsequent work they did confirming the new hormone. It’s a rejig of an older, poorly funded group the trio had worked on called Cardero, but now they’ve managed to convince a fleet of topflight investors: Longitude, Arch, Vertex and Adams Street have joined in an $85 million Series A.